Biosearch and IMDx Finalize cGMP Oligo Supply and Licensing Agreements for IVD Products
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Biosearch Technologies, Inc. (Biosearch), and IMDx (privately held), a developer and manufacturer of molecular tests, have announced that Biosearch has licensed access to the BHQ®, CAL Fluor® and Quasar® patents to IMDx. In addition, Biosearch will manufacture cGMP oligonucleotides for IMDx for use in human in-vitro diagnostics.
“Biosearch Technologies is honored to have been chosen as IMDx’s cGMP oligo provider,” says Marc Beal, Director of Corporate Development at Biosearch Technologies. “IMDx assays, powered by BHQ probing technologies, provide a potent combination for future diagnostic tests.”
“We are very pleased to be working with Biosearch. We believe BHQ probes are very effective, leading to highly differentiated products for many markets,” says Alice Jacobs, MD, Chairman & CEO of IMDx.
“Biosearch Technologies is honored to have been chosen as IMDx’s cGMP oligo provider,” says Marc Beal, Director of Corporate Development at Biosearch Technologies. “IMDx assays, powered by BHQ probing technologies, provide a potent combination for future diagnostic tests.”
“We are very pleased to be working with Biosearch. We believe BHQ probes are very effective, leading to highly differentiated products for many markets,” says Alice Jacobs, MD, Chairman & CEO of IMDx.
